| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yunli Yu, Xinting Wang, Can Liu, Dan Yao, Mengyue Hu, Jia Li, Nan Hu, Li Liu, Xiaodong Li. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicology and applied pharmacology. vol 266. issue 3. 2013-05-29. PMID:23200776. |
to clarify the contradiction on elevated glp-1 without insulinotropic effect, effects of glp-1 and gatifloxacin on insulin release were investigated using ins-1 cells. |
2013-05-29 |
2023-08-12 |
rat |
| Yunli Yu, Xinting Wang, Can Liu, Dan Yao, Mengyue Hu, Jia Li, Nan Hu, Li Liu, Xiaodong Li. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicology and applied pharmacology. vol 266. issue 3. 2013-05-29. PMID:23200776. |
we found that short exposure (2h) to glp-1 stimulated insulin secretion and biosynthesis, whereas long exposure (24 h and 48 h) to high level of glp-1 inhibited insulin secretion and biosynthesis. |
2013-05-29 |
2023-08-12 |
rat |
| Yunli Yu, Xinting Wang, Can Liu, Dan Yao, Mengyue Hu, Jia Li, Nan Hu, Li Liu, Xiaodong Li. Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicology and applied pharmacology. vol 266. issue 3. 2013-05-29. PMID:23200776. |
all the results gave an inference that gatifloxacin stimulated over-secretion of glp-1, in turn, high levels of glp-1 and gatifloxacin synergistically impaired insulin release, worsening hyperglycemia. |
2013-05-29 |
2023-08-12 |
rat |
| M R Rekha, Chandra P Sharm. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives. International journal of pharmaceutics. vol 440. issue 1. 2013-05-28. PMID:22503954. |
in this review we are focusing on the advances reported during the past decade in the field of oral insulin delivery along with the possibility of other peptidic incretin hormones such as glp-1, exendin-4, for diabetes therapy. |
2013-05-28 |
2023-08-12 |
Not clear |
| M A Hussain, C Stratakis, L Kirschne. Prkar1a in the regulation of insulin secretion. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 44. issue 10. 2013-05-28. PMID:22951902. |
an effective treatment of t2dm with incretin hormone glucagon-like peptide-1 (glp-1) or its long acting peptide analogue exendin-4 (e4), restores first-phase and augments second-phase glucose stimulated insulin secretion. |
2013-05-28 |
2023-08-12 |
human |
| M Seghieri, E Rebelos, A Gastaldelli, B D Astiarraga, A Casolaro, E Barsotti, A Pocai, M Nauck, E Muscelli, E Ferrannin. Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. vol 56. issue 1. 2013-05-28. PMID:23064290. |
glucagon-like peptide-1 (glp-1) lowers glucose levels by potentiating glucose-induced insulin secretion and inhibiting glucagon release. |
2013-05-28 |
2023-08-12 |
Not clear |
| Claudia E Reusch, Isabelle Padrut. New incretin hormonal therapies in humans relevant to diabetic cats. The Veterinary clinics of North America. Small animal practice. vol 43. issue 2. 2013-05-13. PMID:23522180. |
incretins (gastric inhibitory polypeptide and glucagon-like peptide 1 [glp-1]) are hormones released from the gastrointestinal tract during food intake that potentiate insulin secretion. |
2013-05-13 |
2023-08-12 |
Not clear |
| Claudia E Reusch, Isabelle Padrut. New incretin hormonal therapies in humans relevant to diabetic cats. The Veterinary clinics of North America. Small animal practice. vol 43. issue 2. 2013-05-13. PMID:23522180. |
in healthy cats, glp-1 agonists and dpp-4 inhibitors have produced a substantial increase in insulin secretion. |
2013-05-13 |
2023-08-12 |
Not clear |
| Cicero L T Chang, Yenshou Lin, Arlene P Bartolome, Yi-Ching Chen, Shao-Chih Chiu, Wen-Chin Yan. Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evidence-based complementary and alternative medicine : eCAM. vol 2013. 2013-05-13. PMID:23662132. |
in this review, we select and discuss blood glucose-lowering medicinal herbs that have the ability to modulate one or more of the pathways that regulate insulin resistance, β-cell function, glp-1 homeostasis, and glucose (re)absorption. |
2013-05-13 |
2023-08-12 |
Not clear |
| E Ekholm, N Shaat, J J Hols. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta diabetologica. vol 49. issue 5. 2013-04-29. PMID:21761282. |
clinical characteristics and biochemical data (glucose, proinsulin, insulin, c-peptide, glp-1 and gip) during a test meal were compared between mody patients from eight different families. |
2013-04-29 |
2023-08-12 |
human |
| E Ekholm, N Shaat, J J Hols. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta diabetologica. vol 49. issue 5. 2013-04-29. PMID:21761282. |
no such correlation was seen for insulin and glp-1. |
2013-04-29 |
2023-08-12 |
human |
| E Ekholm, N Shaat, J J Hols. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta diabetologica. vol 49. issue 5. 2013-04-29. PMID:21761282. |
auc insulin during the test meal was strongly correlated with gip secretion, whereas no such correlation was seen for insulin and glp-1. |
2013-04-29 |
2023-08-12 |
human |
| E Ekholm, N Shaat, J J Hols. Characterization of beta cell and incretin function in patients with MODY1 (HNF4A MODY) and MODY3 (HNF1A MODY) in a Swedish patient collection. Acta diabetologica. vol 49. issue 5. 2013-04-29. PMID:21761282. |
thus, gip may be a more important factor for insulin secretion than glp-1 in mody patients. |
2013-04-29 |
2023-08-12 |
human |
| Wei-Na Han, Christian Hölscher, Li Yuan, Wei Yang, Xiao-Hui Wang, Mei-Na Wu, Jin-Shun Q. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats. Neurobiology of aging. vol 34. issue 2. 2013-04-29. PMID:22592020. |
liraglutide, a novel long-lasting glucagon-like peptide 1 (glp-1) analog, facilitates insulin signaling and shows neuroprotective properties. |
2013-04-29 |
2023-08-12 |
rat |
| Giorgio Sest. [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients]. Giornale italiano di cardiologia (2006). vol 13. issue 12 Suppl 1. 2013-04-29. PMID:23258124. |
glp-1 analogs increase insulin secretion and inhibit glucagon secretion in a glucose-dependent manner, thus conferring glycemic control with a low risk of hypoglycemia. |
2013-04-29 |
2023-08-12 |
Not clear |
| Giorgio Sest. [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients]. Giornale italiano di cardiologia (2006). vol 13. issue 12 Suppl 1. 2013-04-29. PMID:23258124. |
the combination of glp-1 analogs and insulin might be highly effective to maintain glucose control, and to attenuate the adverse effects usually associated with insulin therapy. |
2013-04-29 |
2023-08-12 |
Not clear |
| Giorgio Sest. [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients]. Giornale italiano di cardiologia (2006). vol 13. issue 12 Suppl 1. 2013-04-29. PMID:23258124. |
data from both retrospective and prospective clinical studies support the therapeutic potential of the combination of glp-1 analogs and insulin, usually showing beneficial effects on glycemic control associated with reduced weight gain, low incidence of hypoglycemia and, in established insulin therapy, reduction in insulin dose. |
2013-04-29 |
2023-08-12 |
Not clear |
| Francis S Willard, Denise Wootten, Aaron D Showalter, Emilia E Savage, James Ficorilli, Thomas B Farb, Krister Bokvist, Jorge Alsina-Fernandez, Sebastian G B Furness, Arthur Christopoulos, Patrick M Sexton, Kyle W Sloo. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Molecular pharmacology. vol 82. issue 6. 2013-04-23. PMID:22930710. |
therefore, we tested the hypothesis that selectively modulating the low-affinity glp-1 receptor agonist, oxyntomodulin, would improve the insulin secretory properties of this naturally occurring hormone to provide a rationale for pursuing an unexplored therapeutic approach. |
2013-04-23 |
2023-08-12 |
Not clear |
| Jun Hou, Dezhi Zheng, Kaihua Fan, Botao Yu, Wenjing Xiao, Jie Ma, Weihua Jin, Yonghong Tan, Juan W. Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. Pharmacology. vol 90. issue 3-4. 2013-04-22. PMID:22948814. |
in addition, the combination therapy improved glucose tolerance with an increase in plasma insulin level and active glp-1 levels. |
2013-04-22 |
2023-08-12 |
rat |
| David P Sonne, Kristine J Hare, Pernille Martens, Jens F Rehfeld, Jens J Holst, Tina Vilsbøll, Filip K Kno. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. American journal of physiology. Gastrointestinal and liver physiology. vol 304. issue 4. 2013-04-19. PMID:23275610. |
basal and postprandial plasma concentrations of glucose, insulin, c-peptide, glucagon, glp-1, glucose-dependent insulinotropic polypeptide (gip), glucagon-like peptide-2 (glp-2), cholecystokinin (cck), and gastrin were measured. |
2013-04-19 |
2023-08-12 |
human |